LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aktien・Arvinas Inc

Arvinas Inc

Geschlossen

BrancheGesundheitswesen

9.08 -3.51

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.86

Max

9.38

Schlüsselkennzahlen
By Trading Economics
Einkommen	9.8M -58M
Verkäufe	6.1M 16M
EPS	-0.9
Gewinnspanne	-369.231
Angestellte	246
EBITDA	2.2M -64M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+61.36% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-280M 623M
Vorheriger Eröffnungskurs	12.59
Vorheriger Schlusskurs	9.08

Nachrichtenstimmung

By Acuity

36%

64%

110 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.55 / 9.11 Unterstützung & Widerstand

Arvinas Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2026, 22:47 UTC

Heiße Aktien

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. Mai 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. Mai 2026, 22:00 UTC

Wichtige Markttreiber

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. Mai 2026, 18:09 UTC

Wichtige Markttreiber

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15. Mai 2026, 16:02 UTC

Ergebnisse

Wichtige Markttreiber

Forward Industries Shares Fall on New Debt as Solana Value Drops

15. Mai 2026, 14:55 UTC

Wichtige Markttreiber

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15. Mai 2026, 14:43 UTC

Wichtige Markttreiber

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15. Mai 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. Mai 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. Mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 20:19 UTC

Heiße Aktien

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. Mai 2026, 19:41 UTC

Akquisitionen, Fusionen, Übernahmen

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. Mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. Mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. Mai 2026, 18:35 UTC

Ergebnisse

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15. Mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15. Mai 2026, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15. Mai 2026, 16:24 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15. Mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15. Mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15. Mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15. Mai 2026, 15:20 UTC

Ergebnisse

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15. Mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer-Vergleich

Kursveränderung

Arvinas Inc Prognose

Kursziel

By TipRanks

61.36% Vorteil

12-Monats-Prognose

Durchschnitt 15.2 USD 61.36%

Hoch 24 USD

Tief 6 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arvinas Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

Buy

Halten

Sell

Basierend auf 17 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Arvinas Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.55 / 9.11Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There is one bearish event.

Stimmung

By Acuity

110 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.